United States · FDA National Drug Code directory
Enspryng
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 50242-007_488188fd-2edc-44e0-a537-c2bd408caaa2
- Product NDC
- 50242-007
- Form
- INJECTION, SOLUTION
- Composition / generic term
- Satralizumab
- Labeler
- Genentech, Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20200814
- Source listing expiry
- 20271231
Source-listed ingredients
- SATRALIZUMAB — 120 mg/mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 SYRINGE, PLASTIC in 1 CARTON (50242-007-01) / 1 mL in 1 SYRINGE, PLASTIC · 50242-007-01
- 1 SYRINGE in 1 CARTON (50242-007-33) / 1 mL in 1 SYRINGE · 50242-007-33
- 1 SYRINGE, PLASTIC in 1 CARTON (50242-007-55) / 1 mL in 1 SYRINGE, PLASTIC · 50242-007-55
- 1 SYRINGE, PLASTIC in 1 CARTON (50242-007-86) / 1 mL in 1 SYRINGE, PLASTIC · 50242-007-86
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →